Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00425646 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: imatinib mesylate

Sponsor

University of Washington

Collaborators

[object Object]